Transjugular intrahepatic portosystemic shunt insertion is associated with a lower risk for short-term mortality in patients ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
No neoadjuvant treatment has been considered to be standard therapy for patients with resectable intrahepatic cholangiocarcinoma with high-risk factors for recurrence. The GOLP regimen ...
January 30, 2026—Gore & Associates announced European CE Mark approval of a 6- to 10-mm diameter range for the Gore Viatorr TIPS—transjugular intrahepatic portosystemic shunt—endoprosthesis with ...
This article reports the case of a 73-year-old man with a 50-year history of long-term alcohol abuse (with daily intake of 250 g) combined with primary biliary cholangitis (PBC, AMA-M2 positive). The ...
Transjugular intrahepatic portosystemic shunt (TIPS) is an important intervention for relieving portal hypertension-related complications in patients with decompensated cirrhosis. However, ...
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826 The 3-year overall survival (OS) for advanced intrahepatic ...
In patients with cirrhosis and acute fundal variceal bleeding, the use of preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) with a covered stent within 72 hours of initial bleeding ...
In patients with cirrhosis who received a transjugular intrahepatic portosystemic shunt, advanced age was associated with a higher rate of mortality and hepatic encephalopathy 1 year after the ...
aInstitute of Liver Studies, King's College Hospital National Health Services Foundation Trust, London, UK bFetal Medicine Research Unit, King's College Hospital National Health Services Foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results